News|Podcasts|October 7, 2026

Pharmaceutical Executive Daily: FDA Approves Tukysa Plus Trastuzumab and Pertuzumab

Caribou Biosciences discontinues its two allogeneic CAR-T programs, Kamal Biswas makes the case for continuous quality management maturity, and FDA approves Pfizer’s Tukysa as a first-line maintenance therapy in HER2-positive breast cancer.

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.

In today’s Pharmaceutical Executive Daily, Caribou Biosciences discontinues its allogeneic CAR-T programs vispa-cel and Cb-011, Kamal Biswas argues that continuous, AI-enabled quality management maturity can flag a brewing hundred-million-dollar problem months before an FDA inspection would, and FDA approves Pfizer’s Tukysa in combination with trastuzumab and pertuzumab as a first-line maintenance therapy for HER2-positive metastatic breast cancer.

Caribou Biosciences has discontinued its two allogeneic CAR-T programs, vispa-cel, an anti-CD19 therapy for relapsed or refractory B-cell non-Hodgkin lymphoma that the company says is pivotal trial-ready, and Cb-011, an anti-BCMA candidate for relapsed or refractory multiple myeloma that showed deep, durable responses in the Phase I CaMMouflage trial. Chief executive officer Rachel Haurwitz says the financing environment for allogeneic CAR-T therapies has made the programs too difficult to fund and that the decision is in no way a reflection of their belief in patient benefit, as the company cuts most of its workforce by the fourth quarter of 2026 while reviewing strategic alternatives including a merger or sale.

Kamal Biswas argues that passing an FDA inspection says little about whether a major revenue risk is already forming, and that continuous, AI-enabled quality management maturity, or QMM, can surface that risk months before it reaches the P&L. Biswas points to a sample site alert showing a quality maturity score sliding from 4.1 to 3.6 over 90 days as the kind of early warning traditional inspection-based oversight would miss.

Finally, FDA has approved Pfizer’s Tukysa (tucatinib) in combination with trastuzumab and pertuzumab as a first-line maintenance therapy for adults with unresectable locally advanced or metastatic HER2-positive breast cancer. The approval rests on the Phase III HER2CLIMB-05 trial, in which the combination extended median progression-free survival by 8.6 months, to 24.9 months versus 16.3 months with placebo plus the two antibodies, with a hazard ratio of 0.64.

Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.


Related to this article

Pharmaceutical Executive Daily
FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.
Pharmaceutical Executive Daily
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.
Pharmaceutical Executive daily
argenx acquires Unnatural Products for up to $1.15 billion to expand its immunology capabilities, GiftHealth’s Chip Parkinson on how single-partner platforms can transform the prescription journey, and Partha Anbil on why competing on net value matters more than cutting list prices as US drug pricing resets.